Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH

Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis

(2021) Narjes Nasiri-Ansari et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Empagliflozin Alleviates Hepatic Steatosis by Activating the AMPK-TET2-Autophagy Pathway in vivo and in vitro

(2021) Ting Li et al.   Frontiers in Pharmacology

Convergence: Lactosylceramide-Centric Signaling Pathways Induce Inflammation, Oxidative Stress, and Other Phenotypic Outcomes

(2021) Subroto Chatterjee et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway

(2021) Ziyu Meng et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH

(2021) Katharina Luise Hupa-Breier et al.   Biomedicines

Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis

(2020) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease

(2020) Nikolaos Perakakis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name

(2020) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement

(2019) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?

(2019) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

(2019) Sabine Kahl et al.   DIABETES CARE

Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study

(2019) Nikolaos Perakakis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress

(2019) Tamiris Ingrid Petito-da-Silva et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

MetaboAnalystR: an R package for flexible and reproducible analysis of metabolomics data

(2018) Jasmine Chong et al.   BIOINFORMATICS

Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis

(2018) Maria Apostolopoulou et al.   DIABETES CARE

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)

(2018) Mohammad Shafi Kuchay et al.   DIABETES CARE

Pharmacotherapy of type 2 diabetes: An update

(2018) Jagriti Upadhyay et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Omics, big data and machine learning as tools to propel understanding of biological mechanisms and to discover novel diagnostics and therapeutics

(2018) Nikolaos Perakakis et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes

(2018) Ji-Won Kim et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics

(2018) Stergios A. Polyzos et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Pharmacotherapy of obesity: Available medications and drugs under investigation

(2018) Eleni Pilitsi et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

(2016) Teruo Jojima et al.   Diabetology & Metabolic Syndrome

Lactosylceramide-accumulation in lipid-rafts mediate aberrant-autophagy, inflammation and apoptosis in cigarette smoke induced emphysema

(2015) Manish Bodas et al.   APOPTOSIS